Aurinia Pharmaceuticals (AUPH) Revenue (2019 - 2026)

Aurinia Pharmaceuticals has reported Revenue for 8 years, with the latest figure at $77.7 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 24.4% year-over-year to $77.7 million; the trailing twelve-month figure through Mar 2026 stood at $298.3 million (up 20.62% YoY), and the FY2025 full-year result was $283.1 million, up 20.38% from the prior year.
• Revenue for Q1 2026 stood at $77.7 million, up from $77.1 million in the prior quarter.
• The five-year high for Revenue was $77.7 million in Q1 2026, with the low at $21.6 million in Q1 2022.
• Historically, Revenue has averaged $53.3 million across 5 years, with a median of $55.8 million in 2022.
• Annual changes were most pronounced in 2022 — Revenue surged 2265.97% — and 2023, when it retreated 2.27%.
• Aurinia Pharmaceuticals' Revenue stood at $28.4 million in 2022, then soared by 58.59% to $45.1 million in 2023, then soared by 32.76% to $59.9 million in 2024, then grew by 28.81% to $77.1 million in 2025, then gained by 0.77% to $77.7 million in 2026.
• The last three Revenue figures came in at $77.7 million (Q1 2026), $77.1 million (Q4 2025), and $73.5 million (Q3 2025), per Business Quant data.